From Approval to Access: 4 Steps to Rethinking Market Access Strategy in Specialty Pharma

Key Takeaways

• Secure formulary placement by demonstrating clinical and economic value
• Deploy dedicated sales force to educate providers on specialty therapies
• Build trusted pharmacy network after reimbursement pathways confirmed
• Map patient journey to address prior‑auth and financial barriers

Summary

The article outlines a four‑step framework for specialty pharma companies to redesign market‑access strategies as they move from approval to commercial launch. It stresses securing payer formulary placement, deploying a focused sales force, establishing a trusted pharmacy network, and centering the patient experience with support programs. By leveraging specialty pharmacies for real‑world insights, manufacturers can align with payers, providers, and patients. The guidance targets mid‑size firms that prefer in‑house commercialization over licensing.

Pulse Analysis

Specialty pharmaceuticals face a unique market‑access landscape where regulatory approval is only the first hurdle. Mid‑size biotech firms increasingly choose to commercialize their assets internally, confronting complex payer negotiations, fragmented benefit designs, and heightened scrutiny on cost‑effectiveness. In this environment, a holistic access strategy that integrates payer expectations, provider education, and patient support becomes essential for unlocking revenue and ensuring therapies reach those who need them.

The four‑step model presented—formulary placement, sales deployment, pharmacy network establishment, and patient‑centric planning—offers a pragmatic roadmap. Gaining formulary inclusion requires robust clinical data paired with clear budget‑impact analyses, while a dedicated sales team can translate that value proposition into prescriber confidence, especially for rare or newly approved indications. Timing the pharmacy network rollout after reimbursement pathways are secured prevents costly misalignments, and proactive patient‑experience mapping mitigates prior‑authorization delays and financial barriers through bridge programs and copay assistance.

Beyond the individual tactics, the broader implication is a shift toward collaborative, data‑driven access ecosystems. Specialty pharmacies serve as a conduit for real‑world evidence, enabling manufacturers to refine value narratives and adapt support services in real time. By embedding patient‑focused touchpoints—such as refill reminders and pharmacist outreach—companies not only improve adherence but also generate measurable outcomes that reinforce payer negotiations. As the specialty market matures, firms that embed these integrated access strategies will secure stronger market share, sustain long‑term growth, and ultimately enhance patient health.